Literature DB >> 6127097

Beta 2-adrenoceptor agonists and thyroid hormones.

J P Kampmann, T L Svendsen, L Skovsted, J E Mølholm Hansen.   

Abstract

The potential influence of the selective beta 2-adrenoceptor agonist terbutaline on the serum concentration of the thyroid hormones in humans was studied in 11 healthy euthyroid subjects. Five served as a control group without medication while six received 5 mg terbutaline three times daily for 2 weeks. No significant differences were found between the two groups by measuring the serum concentrations of thyroxine, triiodothyronine, reverse triiodothyronine and resin-triiodothyronine uptake. The use of a beta 2-adrenergic receptor stimulating drug is relatively contraindicated in untreated thyrotoxicosis. This recommendation is based upon a summation of clinical adverse reactions and not due to an effect on the serum concentrations of thyroid hormones.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6127097      PMCID: PMC1427640          DOI: 10.1111/j.1365-2125.1982.tb02006.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Asthma and hyperthyroidism.

Authors:  G A Settipane; E Schoenfeld; M W Hamolsky
Journal:  J Allergy Clin Immunol       Date:  1972-06       Impact factor: 10.793

2.  Plasma noradrenaline and adrenaline in patients with thyrotoxicosis and myxoedema.

Authors:  N J Christensen
Journal:  Clin Sci Mol Med       Date:  1973-08

3.  The effect of suppressive therapy of nontoxic diffuse goiter on serum levels of thyroxine, 3,5,3'-triiodothyronine and 3,3',5'-triiodothyronine.

Authors:  K Johansen; J M Hansen; H Perrild; L Skovsted; J P Kampmann
Journal:  Acta Med Scand Suppl       Date:  1979

4.  Thyroid disease and asthma.

Authors:  R K Bush; E N Ehrlich; C E Reed
Journal:  J Allergy Clin Immunol       Date:  1977-05       Impact factor: 10.793

5.  Beta2-adrenergic stimulation of thyroid hormone secretion.

Authors:  A Melander; E Ranklev; F Sundler; U Westgren
Journal:  Endocrinology       Date:  1975-08       Impact factor: 4.736

6.  Thyroid hormone regulation of beta-adrenergic receptor number.

Authors:  L T Williams; R J Lefkowitz; A M Watanabe; D R Hathaway; H R Besch
Journal:  J Biol Chem       Date:  1977-04-25       Impact factor: 5.157

7.  Reduction of plasma triiodothyronine (T3) induced by propranolol.

Authors:  G Lotti; G Delitala; L Devilla; S Alagna; A Masala
Journal:  Clin Endocrinol (Oxf)       Date:  1977-06       Impact factor: 3.478

8.  Failure of propranolol to alter thyroid iodine release, thyroxine turnover, or the TSH and PRL responses to thyrotropin-releasing hormone in patients with thyrotoxicosis.

Authors:  L Wartofsky; R C Dimond; G L Noel; A G Frantz; J M Earll
Journal:  J Clin Endocrinol Metab       Date:  1975-09       Impact factor: 5.958

9.  D-propranolol and DL-propranolol both decrease conversion of L-thyroxine to L-triiodothyronine.

Authors:  P Heyma; R G Larkins; L Higginbotham; K W Ng
Journal:  Br Med J       Date:  1980-07-05

10.  Metabolic and cardiovascular side effects of the beta 2-adrenoceptor agonists salbutamol and rimiterol.

Authors:  P J Phillips; A E Vedig; P L Jones; M G Chapman; M Collins; J B Edwards; T C Smeaton; B M Duncan
Journal:  Br J Clin Pharmacol       Date:  1980-05       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.